转移性前列腺癌的治疗。

IF 1.6 4区 医学 Q3 ONCOLOGY
Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy
{"title":"转移性前列腺癌的治疗。","authors":"Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy","doi":"10.1159/000546930","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.</p><p><strong>Summary: </strong>We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.</p><p><strong>Key messages: </strong>The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-12"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Metastatic Prostate Cancer.\",\"authors\":\"Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy\",\"doi\":\"10.1159/000546930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.</p><p><strong>Summary: </strong>We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.</p><p><strong>Key messages: </strong>The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.</p>\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546930\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:晚期前列腺癌(PCa),特别是转移性去势抵抗性前列腺癌(mCRPC),与显著的发病率和死亡率相关。雄激素受体(AR)信号通路是治疗干预的基石,但耐药机制和疾病进展需要越来越复杂的治疗策略。方法:本文以专家共识为基础,在PubMed (MEDLINE)和ASCO、ASCO GU和ESMO的摘要数据库中进行文献检索。为了说明当前的发展而不要求完整性,选择了新的治疗方法的例子。结果:我们对转移性前列腺癌的治疗进行了全面的概述,强调了治疗方法的发展及其临床意义。雄激素剥夺疗法(ADT)仍然是治疗的支柱,雄激素合成抑制剂、AR抑制剂和新兴的AR降解剂增强了治疗效果。紫杉烷为基础的化疗、镭-223和镥-177 pma -617等放射性药物以及PARP抑制剂扩大了治疗武器库。新的治疗方法正在临床前和临床开发中。在决定最佳治疗策略时,必须考虑到各种因素,包括疾病和患者的具体方面。此外,先前的治疗方法可能会影响后续治疗方法的疗效。结论:越来越多的治疗选择和对肿瘤进展和耐药性发展的生物学过程的更好理解,使晚期前列腺癌患者的个性化治疗日益成为可能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management of Metastatic Prostate Cancer.

Background: Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.

Summary: We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.

Key messages: The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.20
自引率
0.00%
发文量
84
期刊介绍: With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信